Journal of Clinical Pediatrics >

2023 , Vol. 41 >Issue 1: 48 - 53

DOI: https://doi.org/10.12372/jcp.2023.22e0007

General Report

Analysis of the clinical characteristics of epilepsy associated with CHD2 gene variation

  • Fan FENG ,
  • Fang CHEN ,
  • Suzhen SUN ,
  • Xin LI ,
  • Xuefang LIU ,
  • Tong ZHAO
Expand
  • Department of Neurology, Children’s Hospital of Hebei Province, Shijiazhuang 050031, Hebei, China

Received date: 2021-12-31

  Online published: 2023-02-16

Fold

Abstract

Objective To analyze the clinical features of epilepsy in children with CHD2 gene variation. Methods The clinical characteristics and treatment efficacy of 7 children with epilepsy related to CHD2 gene variation were analyzed and summarized. Results The median onset age of seizure in 7 children was 3 years and 2 months old. There were two or more seizure types during the course of the disease in 5 children, and the main seizure was generalized tonic-clonic seizure. Seven children had varying degrees of motor, intellectual and language retardation, and one had a tendency to autism. Abnormal discharge was detected by interictal electroencephalogram in 5 children, and clinical episodes were observed in 4 children. There were no specific changes in skull MRI. More than 2 antiepileptic drugs were needed in 4 children, and the number of seizures decreased after treatment. One patient was not sensitive to antiepileptic drugs and was finally treated with ketogenic diet. At present, the child did not have seizures. The age of the last follow-up was 2 to 7 years old, and seizures were controlled for more than half a year in 3 children. Valproate and levetiracetam are effective drugs for the treatment of CHD2 variation-related epilepsy.Conclusions Children with epilepsy related to CHD2 gene variation have early onset age and various seizure types. Most of the children have refractory epilepsy and poor prognosis, so early intervention should be given.

Key words： CHD2 gene; epilepsy; clonic seizure; developmental retardation

Cite this article

Fan FENG , Fang CHEN , Suzhen SUN , Xin LI , Xuefang LIU , Tong ZHAO . Analysis of the clinical characteristics of epilepsy associated with CHD2 gene variation[J]. Journal of Clinical Pediatrics, 2023 , 41(1) : 48 -53 . DOI: 10.12372/jcp.2023.22e0007

References

[1] Wilson MM, Henshall DC, Byrne SM, et al. CHD2-related CNS pathologies[J]. Int J Mol Sci, 2021, 22(2): 588.
[2] Cardoso AR, Lopes-Marques M, Oliveira M, et al. Genetic variability of the functional domains of chromodomains helicase DNA-Binding (CHD) proteins[J]. Genes (Basel), 2021, 12(11): 1827.
[3] Lamar KJ, Carvill GL. Chromatin remodeling proteins in epilepsy: lessons from CHD2-Associated epilepsy[J]. Front Mol Neurosci, 2018, 11: 208.
[4] Fisher RS, Acevedo C, Arzimanoglou A, et al. ILAE official report: a practical clinical definition of epilepsy[J]. Epilepsia, 2014, 55 (4): 475-482.
[5] EuroEPINOMICS-RES Consortium. Electronic address: euroepinomics-RES@ua.ac.be; Epilepsy Phenome/Genome Project;et al, De Novo Mutations in Synaptic Transmission Genes Including DNM1 Cause Epileptic Encephalopathies[J]. Am J Hum Genet, 2017, 100(1): 179.
[6] Carvill GL, Heavin SB, Yendle SC, et al. Targeted Resequencing in Epileptic Encephalopathies identifies do novo mutations in CHD2 and SYNGAP1[J]. Nat Genat, 2013, 45(7): 825-830.
[7] Chénier S, Yoon G, Argiropoulos B, et al. CHD 2 haplo- insufficiency is associated with developmental delay, intellectual disability, epilepsy and neurobehavioural problems[J]. J Neurodev Disord, 2014, 6(1): 9.
[8] Courage C, Houge G, Gallati S, et al. 15q26.1 Microdeletion encompassing only CHD2 and RGMA in two adults with moderate intellectual disability, epilepsy and truncal obesity[J]. Eur J Med Genet, 2014, 57(9): 520-523.
[9] Lund C, Brodtkorb E, ?ye A M, et al. CHD2 mutations in Lennox-Gastaut syndrome[J]. Epilepsy Behav, 2014, 33: 18-21.
[10] Thomas RH, Zhang LM, Carvill GL, et al. CHD2 myoclonic encephalopathy is frequently associated with self-induced seizures[J]. Neurology, 2015, 84(9): 951-958.
[11] Trivisano M, Striano P, Sartorelli J, et al. CHD2 mutations are a rare cause of generalized epilepsy with myoclonic-atonic seizures[J]. Epilepsy Behav, 2015, 51: 53-56.
[12] Scheffer IE, Berkovic S, Capovilla G, et al. ILAE classification of the epilepsies: position paper of the ILAE Commission for Classification and Terminology[J]. Epilepsia, 2017, 58(4): 512-521.
[13] Zimmern V, Korff C. Status epilepticus in children[J]. Clin Neurophysiol, 2020, 37(5): 429-433.
[14] Carvill GL, Mefford HC. CHD2-Related Neuro-developmental Disorders[M]//Adam MP, Everman DB, Mirzaa GM, et al. GeneReviews?[Internet]. Seattle (WA): University of Washington: 1993-2022.
[15] Thomas RH, Zhang LM, Carvill GL, et al. CHD2 myoclonic encephalopathy is frequently associated with self-induced seizures[J]. Neurology, 2015, 84(9): 951-958.
[16] Firth HV, Richards SM, Bevan AP, et al. DECIPHER: database of chromosomal imbalance and phenotype in humans using ensembl resources[J]. Am J Hum Genet, 2009, 84(4): 524-33.
[17] Galizia EC, Myers CT, Leu C, et al. CHD2 variants are a risk factor for photosensitivity in epilepsy[J]. Brain, 2015, 138(Pt 5): 1198-1207.
[18] Suls A, Jaehn JA, Kecskés A, et al. De novo loss-of-functionmutations in CHD2 cause a fever-sensitive myoclonic epileptic encephalopathy sharing features with Dravet syndrome[J]. Am J Hum Genet, 2013, 93 (5):967-975.
[19] Chen J, Zhang J, Liu A, et al. CHD2-related epilepsy: novel mutations and new phenotypes[J]. Dev Med Child Neurol, 2020, 62(5): 647-653.
[20] Lebrun N, Parent P, Gendras J, et al. Autism spectrum disorder recurrence, resulting of germline mosaicism for a CHD2 gene missense variant[J]. Clin Genet, 2017, 92(6): 669-670.
[21] Veredice C, Bianco F, Contaldo I, et al. Early onset myoclonic epilepsy and 15q26 microdeletion: observation of the first case[J]. Epilepsia, 2009, 50(7): 1810-1815.
[22] Trivisano M, Striano P, Sartorelli J, et al. CHD2 mutations are a rare cause of generalized epilepsy with myoclonic-atonic seizures[J]. Epilepsy Behav, 2015, 51: 53-56.
[23] Singh N, Ritaccio A. Juvenile myoclonic epilepsy mimic associated with CHD2 gene mutation[J]. Epilepsy Behav Rep, 2020, 13: 100355.
[24] Carvill GL, Heavin SB, Yendle SC, et al. Targeted resequencing in epileptic encephalopathies identifies de novo mutations in CHD2 and SYNGAP1[J]. Nat Genet, 2013, 45(7): 825-830.
[25] Cardoso AR, Lopes-Marques M, Oliveira M, et al. Genetic variability of the functional domains of chromodomains helicase DNA-binding (CHD) proteins[J]. Genes (Basel), 2021, 12(11): 1827.
[26] Galizia EC, Myers CT, Leu C, et al. CHD2 variants are a risk factor for photosensitivity in epilepsy[J]. Brain, 2015, 138(Pt 5): 1198-1207.
[27] Pinto AM, Bianciardi L, Mencarelli MA, et al. Exome sequencing analysis in a pair of monozygotic twins re-evaluates the genetics behind their intellectual disability and reveals a CHD2 mutation[J]. Brain Dev, 2016, 38(6): 590-596.
[28] Lebrun N, Parent P, Gendras J, et al. Autism spectrum disorder recurrence, resulting of germline mosaicism for a CHD2 gene missense variant[J]. Clin Genet, 2017, 92(6): 669-670.
[29] Verhoeven WM, Egger JI, Knegt AC, et al. Absence epilepsy and the CHD2 gene: an adolescent male with moderate intellectual disability, short-lasting psychoses, and an interstitial deletion in 15q26.1-q26.2[J]. Neuropsychiatr Dis Treat, 2016, 12: 1135-1139.
[30] 旷小军, 张晓, 宁泽淑, 等. 颈部肌阵挛伴失神发作2例报告并文献复习[J]. 临床儿科杂志, 2021, 39(5):366-369.
[31] Kessler SK, McGinnis E. A practical guide to treatment of childhood absence epilepsy[J]. Paediatr Drugs, 2019, 21(1): 15-24.
Options
Outlines

/

〈 〉

Website Copyright © 2018 Journal of Clinical Pediatrics.
Tel: 021-25076489　E-mail: jcperke@126.com
Powered by Beijing Magtech Co. Ltd